Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.
Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, Degryse S, Canté-Barrett K, Briot D, Clappier E, Lammens T, De Moerloose B, Benoit Y, Poppe B, Meijerink JP, Cools J, Soulier J, Rabbitts TH, Taghon T, Speleman F, Van Vlierberghe P. Peirs S, et al. Among authors: degryse s. Blood. 2014 Dec 11;124(25):3738-47. doi: 10.1182/blood-2014-05-574566. Epub 2014 Oct 9. Blood. 2014. PMID: 25301704 Free article.
HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.
de Bock CE, Demeyer S, Degryse S, Verbeke D, Sweron B, Gielen O, Vandepoel R, Vicente C, Vanden Bempt M, Dagklis A, Geerdens E, Bornschein S, Gijsbers R, Soulier J, Meijerink JP, Heinäniemi M, Teppo S, Bouvy-Liivrand M, Lohi O, Radaelli E, Cools J. de Bock CE, et al. Among authors: degryse s. Cancer Discov. 2018 May;8(5):616-631. doi: 10.1158/2159-8290.CD-17-0583. Epub 2018 Mar 1. Cancer Discov. 2018. PMID: 29496663
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD. Degryse S, et al. Leukemia. 2018 Mar;32(3):788-800. doi: 10.1038/leu.2017.276. Epub 2017 Aug 30. Leukemia. 2018. PMID: 28852199 Free PMC article.
Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.
Vicente C, Schwab C, Broux M, Geerdens E, Degryse S, Demeyer S, Lahortiga I, Elliott A, Chilton L, La Starza R, Mecucci C, Vandenberghe P, Goulden N, Vora A, Moorman AV, Soulier J, Harrison CJ, Clappier E, Cools J. Vicente C, et al. Among authors: degryse s. Haematologica. 2015 Oct;100(10):1301-10. doi: 10.3324/haematol.2015.130179. Epub 2015 Jul 23. Haematologica. 2015. PMID: 26206799 Free PMC article.
Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E, Hornakova T, Springuel L, Degryse S, Gielen O, Cools J, Constantinescu SN, Flex E, Tartaglia M, Renauld JC, Knoops L. Losdyck E, et al. Among authors: degryse s. J Biol Chem. 2015 Nov 27;290(48):29022-34. doi: 10.1074/jbc.M115.670224. Epub 2015 Oct 7. J Biol Chem. 2015. PMID: 26446793 Free PMC article.
Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD. Degryse S, et al. Leukemia. 2018 Dec;32(12):2731. doi: 10.1038/s41375-018-0241-7. Leukemia. 2018. PMID: 30232463 Free PMC article.
16 results